Elaine Siegfried, MD, of Saint Louis University School of Medicine, discusses how the recent guideline update by the American Academy of Dermatology (AAD) affects dermatologists' atopic dermatitis (AD) treatment decisions.
In this interview, Elaine Siegfried, MD, of Saint Louis University School of Medicine, discusses the recent guideline update by the American Academy of Dermatology (AAD) on using phototherapy and systemic therapies to treat patients with atopic dermatitis (AD); she touches on how this update affects dermatologists' treatment decisions.
Siegfried diagnoses and treats skin-related disorders in infants and children; her specialties include AD, psoriasis, vascular birthmarks, and other eczemas. She is interested in research that investigates AD and pediatric drug development, as she participates in clinical trials for new eczema and psoriasis treatments. Siegfried is also a professor of pediatrics and dermatology in the Department of Pediatrics, Division of Dermatology, Saint Louis University School of Medicine.
Transcript
What impact does the AAD guideline update have on the decision-making process for dermatologists when considering different AD treatments?
I, personally, in my world, first of all, I only see children. At least 50% of my patients have atopic dermatitis. I always used to say it was 50% of my population, 90% of my time, because it's such a difficult condition that really requires customized treatment.
Having guidelines like this, and these are guidelines that are strictly geared toward adults, so it doesn't impact my practice at all for, I think the general dermatology population—and it was published in Journal of the American Academy of Dermatology, so it wasn't really so much geared toward allergists, family practice, or internists who also take care of this population of patients.
I would consider it being sort of a loose overview, but, again, even though this was just published, it is now outdated because there are at least 2 other topical medications that we use, and there's going to be newer biologic agents that are currently in the pipeline, and then emerging information about the JAK [Janus kinase] inhibitors. I think it's a very dynamic field, and because there's so many new things that are under development, guidelines are outdated once they're published.
Dr Kathy Zackowski Discusses the Importance of Rehabilitation Research and Trials in MS
April 26th 2024Kathy Zackowski, PhD, National MS Society, expresses the inherent value of quality rehabilitation trials for broadening clinical understandings of multiple sclerosis (MS) and bettering patient outcomes.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Kaiser Permanente was hit by a data breach in mid-April, impacting 13.4 million health plan members; GlaxoSmithKline (GSK) sued Pfizer and BioNTech for allegedly infringing on its messenger RNA technology patents in the companies’ COVID-19 vaccines; the CDC announced the first-known HIV cases transmitted via cosmetic injections.
Read More